{
    "clinical_study": {
        "@rank": "151421", 
        "arm_group": [
            {
                "arm_group_label": "Placebo/Metformin", 
                "arm_group_type": "Placebo Comparator", 
                "description": "patients are administered oral tablets of placebo once daily and 500mg TID for 4 weeks at the run-in period. After randomized ,patients administer the drugs too."
            }, 
            {
                "arm_group_label": "SHR117887 (50mg q.d)/Metformin", 
                "arm_group_type": "Experimental", 
                "description": "patients are administered oral placebo once daily and metformin 500mg TID for 4 weeks at the run-in period.After randomised,patients adminitered SHR117887 50mg QD  and metformin 500mg TID for 12 weeks."
            }, 
            {
                "arm_group_label": "SHR117887 (100mg q.d)/Metformin", 
                "arm_group_type": "Experimental", 
                "description": "patients are administered oral placebo once daily and metformin 500mg TID for 4 weeks at the run-in period.After randomised,patients adminitered SHR117887 100mg QD and metformin 500mg TID for 12 weeks."
            }
        ], 
        "brief_summary": {
            "textblock": "SHR117887 is a new dipeptidyl peptidase(DPP)-4 inhibitor. This study aims to evaluate the\n      efficacy and safety of SHR117887 in combination therapy with Metformin in patients with Type\n      2 Diabetes in Metformin monotherapy Who have Inadequate Glycemic Control"
        }, 
        "brief_title": "Efficacy and Safety Study of SHR117887 in Combination With Metformin in Patients With Type 2 Diabetes", 
        "completion_date": {
            "#text": "August 2013", 
            "@type": "Actual"
        }, 
        "condition": "Type 2 Diabetes", 
        "condition_browse": {
            "mesh_term": [
                "Diabetes Mellitus", 
                "Diabetes Mellitus, Type 2"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Patients diagnosed with type 2 diabetes mellitus\n\n          -  Patients have been treated with metformin for at least 8 weeks and be on a stable\n             dose of at least 1500mg daily prior to the screening visit\n\n          -  HbA1C\uff1a\u22657.5% and \u226411.0% at screeing visit and at the end of run-in period\n\n          -  Age:\u226520 and \u226470 years\n\n          -  BMI(body mass index):\u226520 and \u226435 kg/m2\n\n        Exclusion Criteria:\n\n        -"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "70 Years", 
            "minimum_age": "20 Years"
        }, 
        "enrollment": {
            "#text": "120", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "November 8, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01984489", 
            "org_study_id": "SHR117887-201"
        }, 
        "intervention": [
            {
                "arm_group_label": "Placebo/Metformin", 
                "intervention_name": "Placebo", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": [
                    "SHR117887 (50mg q.d)/Metformin", 
                    "SHR117887 (100mg q.d)/Metformin"
                ], 
                "intervention_name": "SHR117887", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Metformin"
        }, 
        "is_fda_regulated": "No", 
        "keyword": "SHR117887, Metformin,combination,PhaseII", 
        "lastchanged_date": "November 18, 2013", 
        "number_of_arms": "3", 
        "official_title": "A Multicenter Randomized, Double-blind, Placebo Controlled ,Parallel Group ,Phase II Study to Access the Efficacy and Safety of SHR117887 in Combination Therapy With Metformin in Patients With Type 2 Diabetes Patients", 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "China: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "May 2013", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "measure": "Change From Baseline in HbA1c (Hemoglobin A1C) at Week 12", 
            "safety_issue": "No", 
            "time_frame": "12 weeks"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01984489"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Percentage of Participants Achieving Less Than (<) 6.5% or <7% HbA1c Levels", 
                "safety_issue": "No", 
                "time_frame": "12 weeks"
            }, 
            {
                "measure": "Change From Baseline in Fasting Plasma Glucose,insulin and C-peptide at Week 12", 
                "safety_issue": "No", 
                "time_frame": "12 weeks"
            }, 
            {
                "measure": "Post-meal total and incremental glucose,insulin and C-peptide area under the curve at week 12", 
                "safety_issue": "No", 
                "time_frame": "12 weeks"
            }, 
            {
                "measure": "Change From Baseline in Body Weight at Week 12", 
                "safety_issue": "No", 
                "time_frame": "12 weeks"
            }
        ], 
        "source": "Jiangsu HengRui Medicine Co., Ltd.", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Jiangsu HengRui Medicine Co., Ltd.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "June 2012", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "November 2013"
    }
}